menu
    • menu
    [{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LG203003","moa":"DGAT2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Gemigliptin","moa":"Dipeptidyl peptidase IV","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lobeglitazone sulfate","moa":"PPAR-gamma||PPAR?","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LISCure Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LISCure Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LISCure Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LISCure Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LISCure Biosciences \/ Mayo Clinic","highestDevelopmentStatusID":"6","companyTruncated":"LISCure Biosciences \/ Mayo Clinic"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2021","type":"Series B Financing","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LISCure Biosciences","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"LISCure Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LISCure Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Pharmicell Co., Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Autologous Bone Marrow-Derived Msc","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Pharmicell Co., Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmicell Co., Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmicell Co., Inc \/ Undisclosed"},{"orgOrder":0,"company":"JD Bioscience","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GM-60106","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"JD Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JD Bioscience \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"JD Bioscience \/ Novotech"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2025","type":"Licensing Agreement","leadProduct":"OLX75016","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Eli Lilly"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"OLX75016","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX75016","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"J2HBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"J2HBiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"J2HBiotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"J2HBiotech \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OliX Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            OliX Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLX75016

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            OliX, Lilly Ink Global Deal for MASH & Cardiometabolic Indications

                            Details : Under the licensing agreement,Lilly will focus on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis indications.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            February 10, 2025

                            Lead Product(s) : OLX75016

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            D&D Pharmatech

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            D&D Pharmatech

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DD01

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            D&D Pharmatech Granted Fast Track Designation for DD01 for NASH/MASH Treatment

                            Details : DD01 is a proprietary, once-weekly dual agonist of GLP-1 (glucagon-like peptide-1) and glucagon receptors. It is being evaluated for the treatment of adults with non-alcoholic steatohepatitis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 02, 2024

                            Lead Product(s) : DD01

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            J2HBiotech

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            J2HBiotech

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : J2H-1702

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 to Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females

                            Details : J2H-1702 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 13, 2024

                            Lead Product(s) : J2H-1702

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            J2HBiotech

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            J2HBiotech

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males

                            Details : This drug candidate is currently being evaluated in phase I clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 13, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            OliX Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            OliX Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLX75016

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OliX Pharmaceuticals Begins Patient Dosing in Phase 1 Trial of OLX75016 for MASH

                            Details : OLX75016 It is being developed as a novel treatment approach for metabolic dysfunctions associated with non-alcoholic fatty liver disease linked to obesity.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            February 13, 2024

                            Lead Product(s) : OLX75016

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            OliX Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            OliX Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLX75016

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OliX Pharmaceuticals Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug

                            Details : The company has received approval from the Alfred Human Research Ethics Committee to conduct a Phase 1 clinical trial of drug candidate OLX75016 for the treatment of non-alcohol steatohepatitis.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 22, 2023

                            Lead Product(s) : OLX75016

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            LISCure Biosciences

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            LISCure Biosciences

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LB-P8

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA

                            Details : LB-P8, LISCure's microbiome novel drug, as treatment of PSC. LB-P8 is, to the best of company's knowledge, the first drug to be granted orphan drug designation in the field of microbiome-based treatment for metabolic diseases.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            December 08, 2022

                            Lead Product(s) : LB-P8

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            LISCure Biosciences

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            LISCure Biosciences

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LB-P8

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Mee...

                            Details : LB-P6 and LB-P8, targeting autoimmune disease and non-alcoholic steatohepatitis (NASH), respectively. LB-P6 is a candidate substance that is expected to have therapeutic effects on various autoimmune diseases.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            October 28, 2022

                            Lead Product(s) : LB-P8

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            JD Bioscience

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            JD Bioscience

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GM-60106

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First-in-Human Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass In...

                            Details : GM-60106 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 26, 2022

                            Lead Product(s) : GM-60106

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            LG Chem

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            LG Chem

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LG203003

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LG Chem Announces First Subject Enrolled in Phase 1 Clinical Trial of NASH New Drug

                            Details : LG203003 is second NASH compound is formulated to suppress the accumulation of fat in liver cells by selectively impeding the activation of DGAT2 (diacylglycerol O-acyltransferase 2), a triglyceride synthetase, thus reducing liver cell damage.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 14, 2022

                            Lead Product(s) : LG203003

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth